StockDuty ← Dashboard Oct 26, 2026 12:35 AM ET
SignalFDA/Bio

Johnson & Johnson reports response rate for head, neck cancer treatment

Johnson & Johnson reported a response rate for its head and neck cancer treatment.

Johnson & Johnson reported a response rate for its head and neck cancer treatment.
Johnson & Johnson reported a response rate for its head and neck cancer treatment. — impact context not separately stored; see What changed.
Sources